Pfizer Inc. and Blackstone Life Sciences announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of USD 1.5 billion of development costs through 2028 for berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions.

The agreement was announced in a joint press release issued out of New York and Cambridge, Massachusetts.

Funding Tied to Milestones

In exchange for the funding, Blackstone will be eligible to receive milestone-based payments, subject to U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management, and the achievement of certain commercial sales milestones. Any milestone payments, if earned, will be payable to Blackstone over a multi-year period.

Under the terms of the agreement, Blackstone does not acquire any rights or ownership in berobenatide. Pfizer retains full operational control and decision-making with respect to the berobenatide program.

Funds managed by Blackstone's perpetual private equity strategy, BXPE, will invest alongside funds managed by Blackstone Life Sciences as part of the transaction.

Executives Frame the Rationale

Pfizer Chief Financial Officer and Executive Vice President Cecile Guegan said the deal supports the company's approach to funding research.

"Our aim is to bring important new medicines to patients while taking a disciplined approach that pairs internal research investments with targeted investment from capital partners," Guegan said. "Today's announcement helps us advance our comprehensive obesity program and maintain the financial capacity and flexibility to invest in our broader pipeline across all therapeutic areas."

Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences, said the agreement builds on an existing relationship between the two companies.

"We are pleased to further expand our relationship with Pfizer and support the broad and rigorous development of berobenatide as the anchor of Pfizer's cardiometabolic pipeline," Galakatos said. "This collaboration is a good example of our leadership in providing capital solutions at scale to advance important medicines and technologies to patients."

Berobenatide Sits at the Center of a Broad Clinical Program

Berobenatide is being studied for chronic weight management and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea.

According to the announcement, Pfizer plans to advance more than 20 trials for obesity and related comorbidities in 2026. This includes 10 ongoing and planned Phase 3 trials for berobenatide (PF'3944).

The company also said the growing body of evidence supports advancing an extensive development program for berobenatide as a monotherapy and in combination with various Nutrient-Stimulated Hormone (NuSH) peptides, including amylin analogs.

Pfizer characterized berobenatide as a potential first-in-class monthly GLP-1 receptor agonist peptide, distinguishing it from shorter-acting dosing regimens in the GLP-1 class.

What the Deal Means for Pfizer's Balance Sheet

The structure of the agreement ties Blackstone's compensation to regulatory and commercial outcomes rather than granting the investor any stake in the asset itself.

Blackstone's milestone-based payments are contingent on U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management and on specified commercial sales milestones, with any payments spread over multiple years.

For Pfizer, the company framed the arrangement as a way to advance its obesity program while preserving flexibility to invest across its pipeline in all therapeutic areas.

No specific milestones or payment amounts were disclosed beyond the USD 1.5 billion total development cost contribution.

About the Companies

Pfizer, which trades on the New York Stock Exchange under the ticker PFE, describes itself as applying science and global resources to bring therapies to people that extend and significantly improve their lives. The company said it has worked for more than 175 years and routinely posts information important to investors on its website.

Blackstone Life Sciences, based in Cambridge, Massachusetts, is the life sciences arm of Blackstone. The announcement highlighted the firm's role in providing capital solutions at scale for medicines and technologies.

From Coast to Coast: Monitor Every Significant Chemical Project Across the US

How many billion-dollar chemical projects launched in the United States last quarter without ever coming to your attention? For business development teams, suppliers, and contractors in the chemical sector, missed visibility translates to missed revenue.

The Global Project Tracking (GPT) platform by Blackridge Research provides real-time insights specifically tailored for the chemical sector, tracking capital projects across the United States. Rather than aggregating data from various fragmented sources, you gain access to a cohesive, organized pipeline of opportunities primed for engagement.

Whether you're focusing on emerging chemical projects to stay ahead of competitors or tracking ongoing construction to effectively position your products and services, the platform provides your team with the essential project intelligence required for precise outreach planning.

• Upcoming Projects

• Tender Notices

• Contract Awards

• Projects Under Construction

• Completed Projects

Ready to explore the complete US chemical project landscape at a glance? Schedule a Free Demo of the Global Project Tracking (GPT) platform by Blackridge Research today.